The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Open accessAbstract
Background — The purpose of this study was to determine the efficacy of stent-based delivery of sirolimus (SRL) alone or in combination with dexamethasone (DEX) to reduce in-stent neointimal hyperplasia. SRL is a potent immunosuppressive agent that inhibits SMC proliferation by blocking cell cycle progression. Methods and Results — Stents were coated with a nonerodable polymer containing 185 μg SRL, 350 μg DEX, or 185 μg SRL and 350 μg DEX. Polymer biocompatibility studies in the porcine and canine models showed acceptable tissue response at 60 days. Forty-seven stents (metal, n=13; SRL, n=13; DEX, n=13; SRL and DEX, n=8) were implanted in the coronary arteries of 16 pigs. The tissue level of SRL was 97±13 ng/artery, with a stent content of 71±10 μg at 3 days. At 7 days, proliferating cell nuclear antigen and retinoblastoma protein expression were reduced 60% and 50%, respectively, by the SRL stents. After 28 days, the mean neointimal area was 2.47±1.04 mm 2 for the SRL alone and 2.42±1.04 mm 2 for the combination of SRL and DEX compared with the metal (5.06±1.88 mm 2 , P <0.0001) or DEX-coated stents (4.31±3.21 mm 2 , P <0.001), resulting in a 50% reduction of percent in-stent stenosis. Conclusions — Stent-based delivery of SRL via a nonerodable polymer matrix is feasible and effectively reduces in-stent neointimal hyperplasia by inhibiting cellular proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiographic Patterns of In-Stent Restenosis: Classification and Implications for Long-Term Outcome
Mehran, R., Dangas, G., Abizaid, A. S., Mintz, G. S., Lansky, A. J., Satler, L. F., Pichard, A. D., Kent, K. M., Stone, G. W., & Leon, M. B. (1999) · Circulation · doi:10.1161/01.cir.100.18.1872 · Cited by 1,258
Self-citationPathology of Acute and Chronic Coronary Stenting in Humans
Farb, A., Sangiorgi, G., Carter, A. J., Walley, V. M., Edwards, W. D., Schwartz, R. S., & Virmani, R. (1999) · Circulation · doi:10.1161/01.cir.99.1.44 · Cited by 871
Self-citationKornowski, R., Hong, M. K., Tio, F. O., Bramwell, O., Wu, H., & Leon, M. B. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00450-6 · Cited by 844
Self-citationSousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., Seixas, A. C., Staico, R., Mattos, L. A., Sousa, A. G. M. R., et al. (2001) · Circulation · doi:10.1161/01.cir.103.2.192 · Cited by 793
Self-citationRapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells
Marx, S. O., Jayaraman, T., Go, L. O., & Marks, A. R. (1995) · Circulation Research · doi:10.1161/01.res.76.3.412 · Cited by 599
Rapamycin inhibits vascular smooth muscle cell migration.
Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., & Marks, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119038 · Cited by 511
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Grewe, P. H., Deneke, T., Machraoui, A., Barmeyer, J., & Müller, K.-M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00486-6 · Cited by 401
National Cancer Institute (2020) · Definitions · doi:10.32388/f3vp5p · Cited by 383
Newer Immunosuppressive Drugs: A Review
GUMMERT, J. F., IKONEN, T., & MORRIS, R. E. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1061366 · Cited by 248
Frontiers in Interventional Cardiology
Topol, E. J., & Serruys, P. W. (1998) · Circulation · doi:10.1161/01.cir.98.17.1802 · Cited by 247
Carter, A. J., Laird, J. R., Farb, A., Kufs, W., Wortham, D. C., & Virmani, R. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90126-0 · Cited by 229
Self-citationBiocompatibility aspects of new stent technology
Bertrand, O. F., Sipehia, R., Mongrain, R., Rodés, J., Tardif, J.-C., Bilodeau, L., Côté, G., & Bourassa, M. G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00289-7 · Cited by 201
Hårdhammar, P. A., van Beusekom, H. M. M., Emanuelsson, H. U., Hofma, S. H., Albertsson, P. A., Verdouw, P. D., Boersma, E., Serruys, P. W., & van der Giessen, W. J. (1996) · Circulation · doi:10.1161/01.cir.93.3.423 · Cited by 187
Schwartz, R. S., Edwards, W. D., Bailey, K. R., Camrud, A. R., Jorgenson, M., & Holmes, D. R. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.3.395 · Cited by 97
Cited by
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
Self-citationMorice, M.-C., Serruys, P. W., Sousa, J. E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,033
Self-citationPathology of Drug-Eluting Stents in Humans
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., & Virmani, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.042 · Cited by 2,744
Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O., & Kolodgie, F. D. (2004) · Circulation · doi:10.1161/01.cir.0000116202.41966.d4 · Cited by 1,469
Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications
Lüscher, T. F., Steffel, J., Eberli, F. R., Joner, M., Nakazawa, G., Tanner, F. C., & Virmani, R. (2007) · Circulation · doi:10.1161/circulationaha.106.675934 · Cited by 906
Metadata
- Authors
- Suzuki, T., Kopia, G., Hayashi, S.-I., Bailey, L. R., Llanos, G., Wilensky, R., Klugherz, B. D., Papandreou, G., Narayan, P., Leon, M. B., Yeung, A. C., Tio, F., Tsao, P. S., Falotico, R., & Carter, A. J.
- Venue
- Circulation
- Published
- 2001-09-04
- Volume
- 104
- Issue
- 10
- Pages
- 1188-1193
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2121718174
- Cited by
- 708
- References
- 15
- FWCI
- 57.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.